Gilead Sciences, Inc. notes it was an early adopter when it comes to trial diversity because of its historic focus on HIV. But its development of Veklury (remdesivir) brought it into the spotlight when The New England Journal of Medicine published an article in August 2020 highlighting disproportionate enrollment of white participants in the National Institutes of Health’s early trials of the COVID-19 antiviral. That article helped jumpstart the biopharma industry’s current focus on clinical trial diversity.
How Gilead Did Trial Diversity Before It Was Cool
Thanks in part to its HIV focus, Gilead was an early adopter when it came to emphasizing diversity in trials.
More from Diversity & Inclusion
• By
Parexel's CEO Peyton Howell and India boss Sanjay Vyas talk to Scrip about the value of clinical trial diversity, AI pilots underway and opportunities for India amid geopolitical rumblings, as well as the need for standardized regulatory approaches to enhance sponsor interest.
• By
A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.
• By
Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston.
• By
Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees.
More from ESG
• By
The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.
• By
Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees.
• By
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.